Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mei Pharma Inc (MEIP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 113,252
  • Shares Outstanding, K 36,770
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,860 K
  • 36-Month Beta 1.54
  • Price/Sales 4.97
  • Price/Cash Flow N/A
  • Price/Book 2.02

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.02 +52.48%
on 06/20/17
3.26 -5.52%
on 07/07/17
+1.02 (+49.51%)
since 06/19/17
3-Month
1.52 +102.63%
on 04/27/17
3.26 -5.52%
on 07/07/17
+1.55 (+101.31%)
since 04/19/17
52-Week
1.32 +133.33%
on 07/29/16
3.26 -5.52%
on 07/07/17
+1.70 (+123.19%)
since 07/19/16

Most Recent Stories

More News
MEI Pharma (MEIP) Worth a Look: Stock Rises 12% in Session

MEI Pharma, Inc. (MEIP) shares rose over 12% in the last trading session.

ESALY : 53.6200 (-0.26%)
MEIP : 3.08 (+2.33%)
BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase

BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).

VVUS : 1.20 (-2.44%)
BMRN : 87.23 (+0.65%)
MEIP : 3.08 (+2.33%)
REGN : 506.79 (+1.84%)
Concordia International (CXRX) Catches Eye: Stock Jumps 9.9%

Concordia International Corp. (CXRX) moved big last session, as the company saw its shares rise almost 10% on the day.

CXRX : 1.51 (-4.43%)
MEIP : 3.08 (+2.33%)
Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA

Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu.

VVUS : 1.20 (-2.44%)
MEIP : 3.08 (+2.33%)
VRX : 17.25 (+0.52%)
SNY : 46.81 (-1.95%)
KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline

KemPharm, Inc. (KMPH) announced that it has strengthened its attention deficit hyperactivity disorder (ADHD) produg pipeline portfolio.

VVUS : 1.20 (-2.44%)
KMPH : 3.55 (unch)
SHPG : 162.79 (-0.96%)
MEIP : 3.08 (+2.33%)
Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?

Shares of Catalyst Pharmaceuticals, Inc. (CPRX) have soared 161% this year so far, massively outperforming the Zacks classified Medical Drugs industry's gain of 10.2%.

VVUS : 1.20 (-2.44%)
BMRN : 87.23 (+0.65%)
MEIP : 3.08 (+2.33%)
CPRX : 2.93 (+9.74%)
Seattle Genetics (SGEN) Reports Positive Data for Adcetris

Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.

VVUS : 1.20 (-2.44%)
SGEN : 54.00 (+1.26%)
MEIP : 3.08 (+2.33%)
SNY : 46.81 (-1.95%)
Shire (SHPG) Receives MAA Validation for Veyvondi by EMA

Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding...

VVUS : 1.20 (-2.44%)
SHPG : 162.79 (-0.96%)
MEIP : 3.08 (+2.33%)
SNY : 46.81 (-1.95%)
Indivor's Opioid Use Disorder Drug Meets Primary Endpoint

Indivior PLC (INVVY) announced that a pivotal study (RB-US-13-0001) evaluating its candidate, RBP-6000, in patients with moderate-to-severe opioid use disorder (OUD) met its primary endpoint.

VVUS : 1.20 (-2.44%)
MEIP : 3.08 (+2.33%)
REGN : 506.79 (+1.84%)
INVVY : 20.5450 (+2.73%)
Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug

Seattle Genetics, Inc. (SGEN) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma...

VVUS : 1.20 (-2.44%)
SGEN : 54.00 (+1.26%)
MEIP : 3.08 (+2.33%)
SNY : 46.81 (-1.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards,...

See More

Support & Resistance

2nd Resistance Point 3.19
1st Resistance Point 3.13
Last Price 3.08
1st Support Level 2.98
2nd Support Level 2.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.